Gaucher Type News Today

AVROBIO (NASDAQ:AVRO – Get Rating) and Denali Therapeutics (NASDAQ:DNLI – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation. Earnings and Valuation This table compares AVROBIO and Denali Therapeutics’ top-line […]

AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) was the target of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 1,420,000 shares, a growth of 44.4% from the May 15th total of 983,300 shares. Based on an average trading volume of 2,170,000 shares, the days-to-cover […]

Vitro Diagnostics (OTCMKTS:VODG – Get Rating) and AVROBIO (NASDAQ:AVRO – Get Rating) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, dividends and profitability. Profitability This table compares Vitro Diagnostics and AVROBIO’s net margins, return […]

AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) was the target of a significant decrease in short interest in April. As of April 30th, there was short interest totalling 975,800 shares, a decrease of 5.3% from the April 15th total of 1,030,000 shares. Based on an average trading volume of 1,270,000 shares, the short-interest ratio is currently […]

Operator: Good day, everyone. Welcome to the Freeline Therapeutics Business Update Conference Call. At this time, all participants are in listen-only mode.

AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) was the target of a large increase in short interest in the month of February. As of February 15th, there was short interest totalling 753,500 shares, an increase of 504.7% from the January 31st total of 124,600 shares. Approximately 2.0% of the company’s shares are short sold. Based on […]

Shares of AVROBIO, Inc. (NASDAQ:AVRO – Get Rating) have earned an average recommendation of “Buy” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective […]